DKK1 and osteogenesis imperfecta: AGA-2115 (Angitia Biopharmaceuticals) is also a humanized bispecific antibody that targets sclerostin and DKK1 which is in Phase 1 clinical development for the treatment of osteogenesis imperfecta.